Publication: Safety and efficacy of everolimus with exemestane vs. Exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2
Issued Date
2013-01-01
Resource Type
ISSN
19380666
15268209
15268209
Other identifier(s)
2-s2.0-84889008307
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical Breast Cancer. Vol.13, No.6 (2013), 421-432
Suggested Citation
Kathleen I. Pritchard, Howard A. Burris, Yoshinori Ito, Hope S. Rugo, Shaker Dakhil, Gabriel N. Hortobagyi, Mario Campone, Tibor Csöszi, José Baselga, Puttisak Puttawibul, Martine Piccart, Daniel Heng, Shinzaburo Noguchi, Vichien Srimuninnimit, Hugues Bourgeois, Antonio Gonzalez Martin, Karen Osborne, Ashok Panneerselvam, Tetiana Taran, Tarek Sahmoud, Michael Gnant Safety and efficacy of everolimus with exemestane vs. Exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clinical Breast Cancer. Vol.13, No.6 (2013), 421-432. doi:10.1016/j.clbc.2013.08.011 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/31429
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Safety and efficacy of everolimus with exemestane vs. Exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2
Author(s)
Kathleen I. Pritchard
Howard A. Burris
Yoshinori Ito
Hope S. Rugo
Shaker Dakhil
Gabriel N. Hortobagyi
Mario Campone
Tibor Csöszi
José Baselga
Puttisak Puttawibul
Martine Piccart
Daniel Heng
Shinzaburo Noguchi
Vichien Srimuninnimit
Hugues Bourgeois
Antonio Gonzalez Martin
Karen Osborne
Ashok Panneerselvam
Tetiana Taran
Tarek Sahmoud
Michael Gnant
Howard A. Burris
Yoshinori Ito
Hope S. Rugo
Shaker Dakhil
Gabriel N. Hortobagyi
Mario Campone
Tibor Csöszi
José Baselga
Puttisak Puttawibul
Martine Piccart
Daniel Heng
Shinzaburo Noguchi
Vichien Srimuninnimit
Hugues Bourgeois
Antonio Gonzalez Martin
Karen Osborne
Ashok Panneerselvam
Tetiana Taran
Tarek Sahmoud
Michael Gnant
Other Contributor(s)
University of Toronto
Sarah Cannon Research Institute
Cancer Institute Hospital of Japan Foundation for Cancer Research
UCSF Helen Diller Family Comprehensive Cancer Center
Cancer Center of Kansas
University of Texas MD Anderson Cancer Center
Centre de Recherche en Cancérologie
Hetenyi Geza County Hospital
Memorial Sloan-Kettering Cancer Center
Prince of Songkla University
Institut Jules Bordet
University of Calgary
Osaka University
Mahidol University
Centre Jean Bernard
MD Anderson Cancer Center, Madrid
Novartis International AG
Novartis Pharmaceuticals Corporation
Medizinische Universitat Wien
Sarah Cannon Research Institute
Cancer Institute Hospital of Japan Foundation for Cancer Research
UCSF Helen Diller Family Comprehensive Cancer Center
Cancer Center of Kansas
University of Texas MD Anderson Cancer Center
Centre de Recherche en Cancérologie
Hetenyi Geza County Hospital
Memorial Sloan-Kettering Cancer Center
Prince of Songkla University
Institut Jules Bordet
University of Calgary
Osaka University
Mahidol University
Centre Jean Bernard
MD Anderson Cancer Center, Madrid
Novartis International AG
Novartis Pharmaceuticals Corporation
Medizinische Universitat Wien
Abstract
Background Postmenopausal women with hormone receptor-positive (HR+) breast cancer in whom disease progresses or there is recurrence while taking a nonsteroidal aromatase inhibitor (NSAI) are usually treated with exemestane (EXE), but no single standard of care exists in this setting. The BOLERO-2 trial demonstrated that adding everolimus (EVE) to EXE improved progression-free survival (PFS) while maintaining quality of life when compared with EXE alone. Because many women with HR+advanced breast cancer are elderly, the tolerability profile of EVE plus EXE in this population is of interest. Patients and Methods BOLERO-2, a phase III randomized trial, compared EVE (10 mg/d) and placebo (PBO), both plus EXE (25 mg/d), in 724 postmenopausal women with HR+advanced breast cancer recurring/progressing after treatment with NSAIs. Safety and efficacy data in elderly patients are reported at 18-month median follow-up. Results Baseline disease characteristics and treatment histories among the elderly subsets (≥ 65 years, n = 275; ≥ 70 years, n = 164) were generally comparable with younger patients. The addition of EVE to EXE improved PFS regardless of age (hazard ratio, 0.59 [≥ 65 years] and 0.45 [≥ 70 years]). Adverse events (AEs) of special interest (all grades) that occurred more frequently with EVE than with PBO included stomatitis, infections, rash, pneumonitis, and hyperglycemia. Elderly EVE-treated patients had similar incidences of these AEs as did younger patients but had more on-treatment deaths. Conclusion Adding EVE to EXE offers substantially improved PFS over EXE and was generally well tolerated in elderly patients with HR+advanced breast cancer. Careful monitoring and appropriate dose reductions or interruptions for AE management are recommended during treatment with EVE in this patient population. © 2013 Elsevier Inc. All rights reserved.